CVE:COT Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis C$0.04 -0.03 (-41.67%) As of 10/14/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cotinga Pharmaceuticals Inc. (COT.V) Stock (CVE:COT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COT alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.02▼C$0.12Volume1,000 shsAverage Volume20,281 shsMarket CapitalizationC$769.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.Read More… Receive COT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address COT Stock News HeadlinesV BREAKING NEWS: Visa Inc. Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into the Company - VNovember 11, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Inc.May 1, 2024 | wsj.comAlways trust the dataThe latest statements from the President or the Federal Reserve Chairman don’t confuse it. Weiss Ratings uses the data to eliminate bias. And what human isn’t biased? It’s no different for investors. That’s why you need a sober-minded guide through market confusion.June 6, 2025 | Weiss Ratings (Ad)Lexicon Pharmaceuticals Inc.February 14, 2024 | wsj.comAcumen Pharmaceuticals Inc ABOSNovember 5, 2023 | morningstar.comSXTP 60 Degrees Pharmaceuticals, Inc.July 22, 2023 | seekingalpha.com8-K: ENANTA PHARMACEUTICALS INCApril 28, 2023 | marketwatch.comIronwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationFebruary 18, 2023 | seekingalpha.comSee More Headlines COT Stock Analysis - Frequently Asked Questions How have COT shares performed this year? Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 on January 1st, 2025. Since then, COT shares have increased by 0.0% and is now trading at C$0.04. View the best growth stocks for 2025 here. How do I buy shares of Cotinga Pharmaceuticals Inc. (COT.V)? Shares of COT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cotinga Pharmaceuticals Inc. (COT.V) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cotinga Pharmaceuticals Inc. (COT.V) investors own include Primo Water (PRMW), Cascades (CAS), Aurora Cannabis (ACB), Advantage Lithium Corp. (AAL.V) (AAL), InPlay Oil (IPO), Harvest One Cannabis (HVT) and Exchange Income (EIF). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:COT CIKN/A Webcotingapharma.com Phone+1-519-8585157FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow17.50 Book ValueC($0.18) per share Price / Book-0.20Miscellaneous Outstanding Shares21,986,000Free FloatN/AMarket CapC$769.51 thousand OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (CVE:COT) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major shift is coming this July — and Wall Street isn't waiting around. Thanks to a new rule going into e...American Alternative | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cotinga Pharmaceuticals Inc. (COT.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Cotinga Pharmaceuticals Inc. (COT.V) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.